Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» TGR-1202
TGR-1202
TG aims for accelerated approval of lymphoma candidate
BioCentury
Fri, 03/1/19 - 09:37 am
TG Therapeutics
umbralisib
TGR-1202
lymphoma
Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-H
Yahoo/Globe NewsWire
Sun, 12/7/14 - 10:04 am
TGR-1202
chronic lymphocytic leukemia
non-Hodgkin's lymphoma
TG Therapeutics
Tiny Biotech Developing Drugs Akin To Biogen's Rituxan Seen As Potential Buyout Bet
Forbes
Mon, 05/27/13 - 08:17 pm
Biogen Idec
Rituxan
TG Therapeutics
Utuxin
TGR-1202
CLL
chronic lymphocytic leukemia
non-Hodgkin's lymphoma
